Blue Earth touts fluciclovine F-18 research at ASCO GU

By staff writers

February 8, 2021 -- Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting research on its Axumin (fluciclovine F-18) PET radiopharmaceutical at the upcoming American Society for Clinical Oncology Genitourinary (ASCO GU) virtual meeting.

Research will cover the diagnostic utility of fluciclovine F-18 PET in biochemically recurrent prostate cancer based on prior primary treatment modality for localized disease and the impact of those findings on treatment, using fluciclovine F-18 PET/CT for prostate cancer, and fluciclovine F-18 PET in metastatic castration-resistant prostate cancer treated with abiraterone acetate.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking